# Patent

## Title
Organic light emitting host materials

## Abstract

Heteroaryl-aryl compounds such as compounds represented by the Formula:

HT-[Ph1]r-Py-Het-ET

may be used in electronic devices such as organic light-emitting devices. For example, the compounds may be used as an emissive material in an emissive layer.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/735,488 filed Dec. 10, 2012, the entire contents of which is hereby incorporated by reference in its entirety.


BACKGROUND
1. Field
The embodiments relate to emissive compounds for light-emitting layers in devices.
2. Description of the Related Art
Organic light-emitting devices (OLED) are becoming increasingly important in lighting and display applications. OLEDs may include an emissive or light-emitting layer that includes a host material and an emissive component dispersed within the host material. Emissive materials of OLED devices may have problems with low stability. This potential deficiency with emissive materials may contribute to low efficiency and short lifetime of the devices comprising the emissive materials.
SUMMARY
Some embodiments include an emissive compound of formula:




wherein, HT is optionally substituted diphenylamine or optionally substituted phenyl(naphthyl)amine, wherein Ph1 is a p-phenylene, wherein ET is optionally substituted benzimidazol-2-yl, optionally substituted benzoxazol-2-yl, or optionally substituted benzthiazol-2-yl, wherein X is CH or N, and wherein r is 1, 2, 3.

With respect to Formula 1, in some embodiments, HT is unsubstituted diphenylamine, a mono-substituted diphenylamine, a di-substituted diphenylamine, an unsubstituted phenyl(naphthyl)amine, a mono-substituted phenyl(naphthyl)amine, and/or an unsubstituted carbazolyl. In some embodiments, ET is an unsubstituted benzoimidazol-2-yl.
Some embodiments include a compound represented by Formula 1a:

HT-[Ph1]r-Py-Het-ET  Formula 1a

wherein HT is optionally substituted diphenylamine or optionally substituted phenyl(naphthyl)amine; each Ph1 is independently optionally substituted p-phenylene, wherein the p-phenylene directly bonded to HT may optionally form a bond to a phenyl of HT to form a three ring system; Py is optionally substituted pyrazin-2,5-ylene; Het is optionally substituted p-phenylene or optionally substituted pyridin-2,5-ylene; ET is optionally substituted benzimidazol-2-yl, optionally substituted benzoxazol-2-yl, or optionally substituted benzothiazol-2-yl; and r is 1, 2, or 3.

Some embodiments include a compound represented by Formula 2:




wherein Cy1 is a p-phenylene optionally substituted with 1 or 2 substituents independently selected from C1-6 alkyl and F; Cy2 is independently a 2,5-pyridyl optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl and F, or a pyrazine optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl and F; Cy3 is pyridin-2,5-ylene optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl and F, or a p-phenylene optionally substituted with 1 or 2 substituents independently selected from C1-6 alkyl and F; Cy4 and Cy5 are independently optionally substituted phenyl or optionally substituted naphthyl, wherein Cy4 and Cy5 may be joined to form, with the nitrogen atom to which they are attached, a carbazolyl ring system; and Cy6 is 1-phenyl-1H-benzo[d]imidazol-2-yl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-6 alkyl and F.

With respect to Formula 2, in some embodiments Cy1, and Cy2 are independently p-phenylene optionally substituted with 1 or 2 substituents independently selected from C1-6 alkyl and F; Cy4 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl and F; Cy5 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl and F, or a naphth-1-yl or naphth-2-yl optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl and F; and Cy6 is 1-phenyl-1H-benzo[d]imidazol-2-yl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-6 alkyl and F.
Some embodiments include a compound represented by Formula 3:




wherein Cy1 is an optionally substituted p-phenylene; Cy3 is selected from an optionally substituted 2,5-pyrazine-3′-pyridine, and optionally substituted 2,5-pyrazine-2′,5′-phenyl, an optionally substituted 2,5-bi-pyridinyl, an optionally substituted 3,3′-bi-pyridinyl, and an optionally substituted 3,2′:5′,3′′-terpyridinyl; Cy4 and Cy5 are optionally substituted phenyl or optionally substituted naphthyl; and Cy6 is optionally substituted 1-phenyl-1H-benzo[d]imidazol-2-yl.

With respect to Formula 3, in some embodiments Cy1 is an optionally substituted interphenylene, independently optionally substituted with H, F, methyl, ethyl, propyl, or isopropyl; wherein Cy3 is independently optionally substituted with H, F, methyl, ethyl, propyl, or isopropyl; wherein Cy4 is independently optionally substituted with H, F, methyl, ethyl, propyl, or isopropyl; wherein Cy5 is independently optionally substituted with H, F, methyl, ethyl, propyl, or isopropyl; wherein Cy6 is independently optionally substituted with H, F, methyl, ethyl, propyl, or isopropyl.
Some embodiments include optionally substituted [(para-phenylenyl-para-azolyl)]compounds, including optionally substituted N,N-diphenyl-4-(6-(1-phenyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)aniline; N-phenyl-N-(4′-(6-(1-phenyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)-[1,1′-biphenyl]-4-yl)naphthalen-1-amine; 4′-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[3,3′-bipyridin]-6-yl)-N,N-di-p-tolyl-[1,1′-biphenyl]-4-amine; 9,9-dimethyl-N,N-diphenyl-7-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[3,3′-bipyridin]-6-yl)-9H-fluoren-2-amine; N,N-diphenyl-4′-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[3,3′-bipyridin]-6-yl)-[1,1′-biphenyl]-4-amine; 4-methyl-N-(4-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[3,3′-bipyridin]-6-yl)phenyl)-N-(p-tolyl)aniline; N-phenyl-N-(4-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[3,3′-bipyridin]-6-yl)phenyl)naphthalen-1-amine; 9,9-dimethyl-7-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[3,3′-bipyridin]-6-yl)-N,N-di-p-tolyl-9H-fluoren-2-amine; N,N-diphenyl-4′-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[2,3′-bipyridin]-5-yl)-[1,1′-biphenyl]-4-amine; 4′-(3-methyl-6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[2,3′-bipyridin]-5-yl)-N,N-diphenyl-[1,1′-biphenyl]-4-amine, N-phenyl-N-(4′-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[2,3′-bipyridin]-5-yl)-[1,1′-biphenyl]-4-yl)naphthalen-2-amine; N-phenyl-N-(4′-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[2,3′-bipyridin]-5-yl)-[1,1′-biphenyl]-4-yl)naphthalen-1-amine; 4-methyl-N-(4-(6′-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[2,3′-bipyridin]-5-yl)phenyl)-N-(p-tolyl)aniline; N,N-diphenyl-4-(6-(1-phenyl-1H-benzo[d]imidazol-2-yl)-[3,2′:5′,3′′-terpyridin]-6′′-yl)aniline, etc.
Some embodiments include a light-emitting device comprising a compound described herein.
These and other embodiments are described in more detail herein. These and other embodiments are described in more detail herein.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic drawing of an embodiment of an OLED device comprising a compound disclosed herein.
FIG. 2 is a schematic drawing of an embodiment of an OLED device described in Example 2.



DETAILED DESCRIPTION
Unless otherwise indicated, when a compound or chemical structural feature such as aryl is referred to as being “optionally substituted,” it is meant that the feature may have no substituents (i.e. be unsubstituted) or may have one or more substituents. A feature that is “substituted” has one or more substituents. The term “substituent” has the ordinary meaning known to one of ordinary skill in the art. In some embodiments, the substituent may be an ordinary organic moiety known in the art, which may have a molecular weight (e.g. the sum of the atomic masses of the atoms of the substituent) of 15 g/mol to 50 g/mol, 15 g/mol to 100 g/mol, 15 g/mol to 200 g/mol, 15 g/mol to 300 g/mol, or 15 g/mol to 500 g/mol. In some embodiments, the substituent comprises: 0-30, 0-20, 0-10, or 0-5 carbon atoms; and 0-30, 0-20, 0-10, or 0-5 heteroatoms independently selected from: N, O, S, Si, F, Cl, Br, or I; provided that the substituent comprises at least one atom selected from: C, N, O, S, Si, F, Cl, Br, or I. Examples of substituents include, but are not limited to, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, acyl, acyloxy, alkylcarboxylate, thiol, alkylthio, cyano, halo, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxyl, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, etc. In some embodiments, two substituents may combine to form a ring.
As used herein the term “alkyl” has the broadest meaning generally understood in the art, and may include a moiety composed of carbon and hydrogen containing no double or triple bonds. Alkyl may be linear alkyl, branched alkyl, cycloalkyl, or a combination thereof, and in some embodiments, may contain from one to thirty-five carbon atoms. In some embodiments, alkyl may include C1-10 linear alkyl, such as methyl (—CH3), ethyl (—CH2CH3), n-propyl (—CH2CH2CH3), n-butyl (—CH2CH2CH2CH3), n-pentyl (—CH2CH2CH2CH2CH3), n-hexyl (—CH2CH2CH2CH2CH2CH3), etc.; C3-10 branched alkyl, such as C3H7 (e.g. iso-propyl), C4H9 (e.g. branched butyl isomers), C5H11 (e.g. branched pentyl isomers), C6H13 (e.g. branched hexyl isomers), C7H15 (e.g. heptyl isomers), etc.; C3-10 cycloalkyl, such as C3H5 (e.g. cyclopropyl), C4H7 (e.g. cyclobutyl isomers such as cyclobutyl, methylcyclopropyl, etc.), C5H9 (e.g. cyclopentyl isomers such as cyclopentyl, methylcyclobutyl, dimethylcyclopropyl, etc.) C6H11 (e.g. cyclohexyl isomers), C7H13 (e.g. cycloheptyl isomers), etc.; and the like.
As used herein, the term “alkoxy” includes —O-alkyl, such as —OCH3, —OC2H5, —OC3H7 (e.g. propoxy isomers such as isopropoxy, n-propoxy, etc.), —OC4H9 (e.g. butyoxy isomers), —OC5H11 (e.g. pentoxy isomers), —OC6H13 (e.g. hexoxy isomers), —OC7H15 (e.g. heptoxy isomers), etc.
With respect to an optionally substituted moiety such as optionally substituted alkyl, a phrase such as “optionally substituted C1-12 alkyl” refers to a C1-12 alkyl that may be unsubstituted, or may have 1 or more substituents, and does not limit the number of carbon atoms in any substituent. A phrase such as “C1-12 optionally substituted alkyl” refers to unsubstituted C1-12 alkyl, or substituted alkyl wherein both the alkyl parent and all substituents have from 1-12 carbon atoms. Similar conventions may be applied to other optionally substituted moieties such as aryl and heteroaryl.
Substituents on alkyl may be the same as those described generally above, except that alkyl may not have an alkyl substituent. In some embodiments, substituents on alkyl are independently selected from F, Cl, Br, I, CN, CO2H, —O-alkyl, ester groups, acyl, amine groups, and amide groups, and may have a molecular weight of about 15 to about 100 or about 500.
For convenience, the term “molecular weight” is used with respect to a moiety or part of a molecule to indicate the sum of the atomic masses of the atoms in the moiety or part of a molecule, even though it may not be a complete molecule.
The structures associated with some of the chemical names referred to herein are depicted below. These structures may be unsubstituted, as shown below, or a substituent may independently be in any position normally occupied by a hydrogen atom when the structure is unsubstituted. Unless a point of attachment is indicated by




attachment may occur at any position normally occupied by a hydrogen atom.








In some embodiments, a compound is provided represented by the following formulae:













With respect to any relevant formula or structural representation herein, HT may be optionally substituted diphenylamine or optionally substituted phenyl(naphthyl)amine. If the diphenylamine is substituted, it may have 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substituents. In some embodiments, the diphenylamine may have 1, 2, 3, or 4 substituents, or 1 or 2 substituents. If the phenyl(naphthyl)amine is substituted, it may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 substituents. In some embodiments, the phenyl(naphthyl)amine may have 1, 2, 3, or 4 substituents, or 1 or 2 substituents. In some embodiments, some or all of the substituents on HT may have: from 0 to 10 carbon atoms and from 0 to 10 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I (provided that there is at least 1 non-hydrogen atom); and/or a molecular weight of 15 g/mol to 500 g/mol. For example, the substituents may be C1-10 optionally substituted alkyl, such as CH3, C2H5, C3H7, cyclic C3H5, C4H9, cyclic C4H7, C5H11, cyclic C5H9, C6H13, cyclic C6H11, etc., which may be optionally substituted; C1-10 optionally substituted alkoxy; halo, such as F, Cl, Br, I; OH; CN; NO2; C1-6 fluoroalkyl, such as CF3, CF2H, C2F5, etc.; a C1-10 ester such as —O2CCH3, —CO2CH3, —O2CC2H5, —CO2C2H5, —O2C-phenyl, —CO2-phenyl, etc.; a C1-10 ketone such as —COCH3, —COC2H5, —COC3H7, —CO-phenyl, etc.; or C1-10 amino such as NH2, NH(CH3), N(CH3)2, N(CH3)C2H5, etc. In some embodiments, any substituents on HT can be an electron donating substituent, such as C1-3 alkyl, C1-3 —O-alkyl, NH3, or C1-3 amino. In some embodiments, HT is unsubstituted.
In some embodiments, HT is:




In some embodiments, HT can be selected from optionally substituted carbozolyl, optionally substituted diphenylamine and/or optionally substituted phenyl(naphthyl)amine with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 substituents independently selected from C1-6 alkyl and F. In some embodiments, HT is selected from unsubstituted diphenylamine, a mono-substituted diphenylamine, a di-substituted diphenylamine, an unsubstituted phenyl(naphthyl)amine, a mono-substituted phenyl(naphthyl)amine, and/or an unsubstituted carbazolyl. Examples of the described ring systems may include any one of the following:







In some embodiments, HT is selected any one of




With respect to any relevant formula or structural representation herein, Ph1a may be optionally substituted p-phenylene, or HT-Ph1a may be 9-phenylcarbazol-3-yl. If the p-phenylene is substituted, it may have 1, 2, 3, or 4 substituents. In some embodiments, the p-phenylene is unsubstituted. In some embodiments the p-phenylene has 1 substituent. In some embodiments, the p-phenylene has 2 substituents. In some embodiments the p-phenylene has 3 substituents. In some embodiments the p-phenylene has 4 substituents. If the 9-phenylcarbazol-3-yl is substituted, it may have it may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, or 12 substituents. In some embodiments, the 9-phenylcarbazol-3-yl may have 1, 2, 3, or 4 substituents, or 1 or 2 substituents. In some embodiments, some or all of the substituents on Ph1a or HT-Ph1a may have: from 0 to 10 carbon atoms and from 0 to 10 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I (provided that there is at least 1 non-hydrogen atom); and/or a molecular weight of 15 g/mol to 500 g/mol. For example, the substituents may be C1-10 optionally substituted alkyl, such as CH3, C2H5, C3H7, cyclic C3H5, C4H9, cyclic C4H7, C5H11, cyclic C5H9, C6H13, cyclic C6H11, etc., which may be optionally substituted; C1-10 optionally substituted alkoxy; halo, such as F, Cl, Br, I; OH; CN; NO2; C1-6 fluoroalkyl, such as CF3, CF2H, C2F5, etc.; a C1-10 ester such as —O2CCH3, —CO2CH3, —O2CC2H5, —CO2C2H5, —O2C-phenyl, —CO2-phenyl, etc.; a C1-10 ketone such as —COCH3, —COC2H5, —COC3H7, —CO-phenyl, etc.; or C1-10 amino such as NH2, NH(CH3), N(CH3)2, N(CH3)C2H5, etc. In some embodiments, any substituents on Ph1a or HT-Ph1a can be C1-3 alkyl, C1-3 —O-alkyl, NH3, or C1-3 amino. In some embodiments, Ph1a or HT-Ph1a is unsubstituted.
In some embodiments, Ph1a is:




In some embodiments, HT-Ph1a is:




With respect to any relevant formula or structural representation herein, Ph1b may be a bond or optionally substituted p-phenylene. If the p-phenylene is substituted, it may have 1, 2, 3, or 4 substituents. In some embodiments, the p-phenylene is unsubstituted. In some embodiments the p-phenylene has 1 substituent. In some embodiments, the p-phenylene has 2 substituents. In some embodiments the p-phenylene has 3 substituents. In some embodiments the p-phenylene has 4 substituents. In some embodiments, some or all of the substituents on Ph1b may have: from 0 to 10 carbon atoms and from 0 to 10 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I (provided that there is at least 1 non-hydrogen atom); and/or a molecular weight of 15 g/mol to 500 g/mol. For example, the substituents may be C1-10 optionally substituted alkyl, such as CH3, C2H5, C3H7, cyclic C3H5, C4H9, cyclic C4H7, C5H11, cyclic C5H9, C6H13, cyclic C6H11, etc., which may be optionally substituted; C1-10 optionally substituted alkoxy; halo, such as F, Cl, Br, I; OH; CN; NO2; C1-6 fluoroalkyl, such as CF3, CF2H, C2F5, etc.; a C1-10 ester such as —O2CCH3, —CO2CH3, —O2CC2H5, —CO2C2H5, —O2C-phenyl, —CO2-phenyl, etc.; a C1-10 ketone such as —COCH3, —COC2H5, —COC3H7, —CO-phenyl, etc.; or C1-10 amino such as NH2, NH(CH3), N(CH3)2, N(CH3)C2H5, etc. In some embodiments, any substituents on Ph1b can be C1-3 alkyl, CF3, or F. In some embodiments, Ph1b is a bond.
With respect to any relevant formula or structural representation herein, Ph1c may be a bond or optionally substituted p-phenylene. If the p-phenylene is substituted, it may have 1, 2, 3, or 4 substituents. In some embodiments, the p-phenylene is unsubstituted. In some embodiments the p-phenylene has 1 substituent. In some embodiments, the p-phenylene has 2 substituents. In some embodiments the p-phenylene has 3 substituents. In some embodiments the p-phenylene has 4 substituents. In some embodiments, some or all of the substituents on Ph1c may have: from 0 to 10 carbon atoms and from 0 to 10 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I (provided that there is at least 1 non-hydrogen atom); and/or a molecular weight of 15 g/mol to 500 g/mol. For example, the substituents may be C1-10 optionally substituted alkyl, such as CH3, C2H5, C3H7, cyclic C3H5, C4H9, cyclic C4H7, C5H11, cyclic C5H9, C6H13, cyclic C6H11, etc., which may be optionally substituted; C1-10 optionally substituted alkoxy; halo, such as F, Cl, Br, I; OH; CN; NO2; C1-6 fluoroalkyl, such as CF3, CF2H, C2F5, etc.; a C1-10 ester such as —O2CCH3, —CO2CH3, —O2CC2H5, —CO2C2H5, —O2C-phenyl, —CO2-phenyl, etc.; a C1-10 ketone such as —COCH3, —COC2H5, —COC3H7, —CO-phenyl, etc.; or C1-10 amino such as NH2, NH(CH3), N(CH3)2, N(CH3)C2H5, etc. In some embodiments, any substituents on Ph1c can be C1-3 alkyl, CF3, or F. In some embodiments, Ph1c is a bond.
With respect to any relevant formula or structural representation herein, Py may be optionally substituted pyrazin-2,5-ylene. If the pyrazin-2,5-ylene is substituted, it may have 1, 2, 3, or 4 substituents. In some embodiments, the pyrazin-2,5-ylene is unsubstituted. In some embodiments the pyrazin-2,5-ylene has 1 substituent. In some embodiments, the pyrazin-2,5-ylene has 2 substituents. In some embodiments, some or all of the substituents on Py may have: from 0 to 10 carbon atoms and from 0 to 10 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I (provided that there is at least 1 non-hydrogen atom); and/or a molecular weight of 15 g/mol to 500 g/mol. For example, the substituents may be C1-10 optionally substituted alkyl, such as CH3, C2H5, C3H7, cyclic C3H5, C4H9, cyclic C4H7, C5H11, cyclic C5H9, C6H13, cyclic C6H11, etc., which may be optionally substituted; C1-10 optionally substituted alkoxy; halo, such as F, Cl, Br, I; OH; CN; NO2; C1-6 fluoroalkyl, such as CF3, CF2H, C2F5, etc.; a C1-10 ester such as —O2CCH3, —CO2CH3, —O2CC2H5, —CO2C2H5, —O2C-phenyl, —CO2-phenyl, etc.; a C1-10 ketone such as —COCH3, —COC2H5, —COC3H7, —CO-phenyl, etc.; or C1-10 amino such as NH2, NH(CH3), N(CH3)2, N(CH3)C2H5, etc. In some embodiments, any substituents on Py can be C1-3 alkyl, CF3, or F. In some embodiments, Py is unsubstituted.
In some embodiments, Py is:




With respect to any relevant formula or structural representation herein, Het may be optionally substituted p-phenylene or optionally substituted pyridin-2,5-ylene. If the p-phenylene is substituted, it may have 1, 2, 3, or 4 substituents. In some embodiments, the p-phenylene is unsubstituted. In some embodiments the p-phenylene has 1 substituent. In some embodiments, the p-phenylene has 2 substituents. In some embodiments the p-phenylene has 3 substituents. In some embodiments the p-phenylene has 4 substituents. If the pyridin-2,5-ylene is substituted, it may have 1, 2, or 3 substituents. In some embodiments, the pyridin-2,5-ylene is unsubstituted. In some embodiments the pyridin-2,5-ylene has 1 substituent. In some embodiments, the pyridin-2,5-ylene has 2 substituents. In some embodiments the pyridin-2,5-ylene has 3 substituents. In some embodiments, some or all of the substituents on Het may have: from 0 to 10 carbon atoms and from 0 to 10 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I (provided that there is at least 1 non-hydrogen atom); and/or a molecular weight of 15 g/mol to 500 g/mol. For example, the substituents may be C1-10 optionally substituted alkyl, such as CH3, C2H5, C3H7, cyclic C3H5, C4H9, cyclic C4H7, C5H11, cyclic C5H9, C6H13, cyclic C6H11, etc., which may be optionally substituted; C1-10 optionally substituted alkoxy; halo, such as F, Cl, Br, I; OH; CN; NO2; C1-6 fluoroalkyl, such as CF3, CF2H, C2F5, etc.; a C1-10 ester such as —O2CCH3, —CO2CH3, —O2CC2H5, —CO2C2H5, —O2C-phenyl, —CO2-phenyl, etc.; a C1-10 ketone such as —COCH3, —COC2H5, —COC3H7, —CO-phenyl, etc.; or C1-10 amino such as NH2, NH(CH3), N(CH3)2, N(CH3)C2H5, etc. In some embodiments, any substituents on Het can be C1-3 alkyl, CF3, or F. In some embodiments, Het is unsubstituted.
In some embodiments, Het is:




With respect to any relevant formula or structural representation herein, ET may be optionally substituted benzimidazol-2-yl, optionally substituted benzoxazol-2-yl, or optionally substituted benzothiazol-2-yl. If the benzimidazol-2-yl, benzoxazol-2-yl, or benzothiazol-2-yl is substituted, it may have 1, 2, 3, or 4 substituents. In some embodiments, the benzimidazol-2-yl, benzoxazol-2-yl, or benzothiazol-2-yl is unsubstituted. In some embodiments the benzimidazol-2-yl, benzoxazol-2-yl, or benzothiazol-2-yl has 1 substituent. In some embodiments, the benzimidazol-2-yl, benzoxazol-2-yl, or benzothiazol-2-yl has 2 substituents. In some embodiments the benzimidazol-2-yl, benzoxazol-2-yl, or benzothiazol-2-yl has 3 substituents. In some embodiments the benzimidazol-2-yl, benzoxazol-2-yl, or benzothiazol-2-yl has 4 substituents.
In some embodiments, ET is optionally substituted 1-phenyl-1H-benzo[d]imidazol-2-yl. In some embodiments, the 1-phenyl-1H-benzo[d]imidazol-2-yl is unsubstituted. If the 1-phenyl-1H-benzo[d]imidazol-2-yl is substituted, it can have 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents. In some embodiments, the 1-phenyl-1H-benzo[d]imidazol-2-yl has 1, 2, 3, or 4 substituents. In some embodiments, the 1-phenyl-1H-benzo[d]imidazol-2-yl has 1 or 2 substituents. In some embodiments, some or all of the substituents on ET may have: from 0 to 10 carbon atoms and from 0 to 10 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I (provided that there is at least 1 non-hydrogen atom); and/or a molecular weight of 15 g/mol to 500 g/mol. For example, the substituents may be C1-10 optionally substituted alkyl, such as CH3, C2H5, C3H7, cyclic C3H5, C4H9, cyclic C4H7, C5H11, cyclic C5H9, C6H13, cyclic C6H11, etc., which may be optionally substituted; C1-10 optionally substituted alkoxy; halo, such as F, Cl, Br, I; OH; CN; NO2; C1-6 fluoroalkyl, such as CF3, CF2H, C2F5, etc.; a C1-10 ester such as —O2CCH3, —CO2CH3, —O2CC2H5, —CO2C2H5, —O2C-phenyl, —CO2-phenyl, etc.; a C1-10 ketone such as —COCH3, —COC2H5, —COC3H7, —CO-phenyl, etc.; or C1-10 amino such as NH2, NH(CH3), N(CH3)2, N(CH3)C2H5, etc. In some embodiments, any substituents on ET can be C1-3 alkyl, or an electron withdrawing substituent such as F, Cl, NO2, CN, COH, COCH3, etc. In some embodiments, ET is unsubstituted.
In some embodiments, ET is:




In some embodiments, ET can be selected from optionally substituted benzimidazol-2-yl, optionally substituted benzoxazol-2-yl, and/or optionally substituted benzthiazol-2-yl. In some embodiments, ET is an unsubstituted benzoimidazol-2-yl. In some embodiments, ET is selected from




In some embodiments, ET is an optionally substituted benzimidazol-2-yl.





In some embodiments, ET is





With respect to any relevant formula above, Ph1 and/or Ph2 can be an optionally substituted p-phenylene.
With respect to any relevant formula above, X can be selected from C and N, e.g., Formula 3 and/or 2 respectively.
In some embodiments, Ph1 is optionally substituted p-phenylene with 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and F. In some embodiments, Ph1 is an unsubstituted p-phenylene.
In some embodiments, Ph2 is optionally substituted p-phenylene with 1, 2, 3 or 4 substituents independently selected from C1-6 alkyl and F. In some embodiments, Ph2 is an unsubstituted p-phenylene.
Generally R1-R35, may be H or any substituent, such as a substituent having from 0 to 6 carbon atoms and from 0 to 5 heteroatoms, wherein each heteroatom is independently: O, N, S, F, Cl, Br, or I, and/or having a molecular weight of 15 g/mol to 300 g/mol. Any of R1-R35 may comprise: a) 1 or more alkyl moieties optionally substituted with, or optionally connected by or to, b) 1 or more functional groups, such as C═C, C≡C, CO, CO2, CON, NCO2, OH, SH, O, S, N, N═C, F, Cl, Br, I, CN, NO2, CO2H, NH2, etc.; or may be a substituent having no alkyl portion, such as F, Cl, Br, I, NO2, CN, NH2, OH, COH, CO2H, etc.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R1 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R1 may be may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R1 may be H.




Each RA may independently be H, or C1-12 alkyl, including: linear or branched alkyl having a formula CaHa+1, or cycloalkyl having a formula CaHa−1, wherein a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, such as linear or branched alkyl of a formula: CH3, C2H5, C3H7, C4H9, C5H11, C6H13, C7H15, C8H17, C9H19, C10H21, etc., or cycloalkyl of a formula: C3H5, C4H7, C5H9, C6H11, C7H13, C8H15, C9H17, C10H19, etc. In some embodiments, RA may be H or C1-6 alkyl. In some embodiments, RA may be H or C1-3 alkyl. In some embodiments, RA may be H or CH3. In some embodiments, RA may be H.
Each RB may independently be H, or C1-12 alkyl, including: linear or branched alkyl having a formula CaHa+1, or cycloalkyl having a formula CaHa, wherein a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, such as linear or branched alkyl of a formula: CH3, C2H5, C3H7, C4H9, C5H11, C6H13, C8H17, C7H15, C9H19, C10H21, etc., or cycloalkyl of a formula: C3H5, C4H7, C5H9, C6H11, C7H13, C8H15, C9H17, C10H19, etc. In some embodiments, RB may be H or C1-3 alkyl. In some embodiments, RB may be H or CH3. In some embodiments, RB may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R2 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R2 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R2 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R3 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R3 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R3 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R4 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R4 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R4 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R5 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R5 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R5 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R6 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R6 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R6 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R7 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R7 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R7 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R8 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R8 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H6, —COC5H11, etc. In some embodiments, R8 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R9 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R9 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R9 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R9a may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R10 may be H; F; Cl; CN; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; C1-6 amino, such as —NHCH3, —NH(CH3)2, —NHCH2CH3, etc.; C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R10 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R10 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R10 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R10 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R11 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R11 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R11 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R12 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R12 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R12 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R13 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R13 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R13 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R14 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R14 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R14 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R15 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R15 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R15 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R16 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R16 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6—CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R16 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R17 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R17 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R17 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R18 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R18 may be H; F; Cl; CN; CF3; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; CHO; C2-6 —CO-alkyl, such as —COCH3, —COC2H5, —COC3H7, COC4H9, —COC5H11, etc.; CO2H; C2-6 —CO2-alkyl, —CO2CH3, —CO2C2H5, —CO2C3H7, CO2C4H9, —COC5H11, etc. In some embodiments, R18 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R19 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R19 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R19 may be H. In some embodiments R19 is methyl.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R20 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R20 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R20 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R21 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R21 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R21 may be H. In some embodiments R21 is methyl.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R22 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R22 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R22 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R23 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R23 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R23 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R24 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R24 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R24 may be H. In some embodiments R24 is methyl.
In some embodiments, R19 and R24 are methyl.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R25 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R25 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R25 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R26 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R26 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R26 may be H. In some embodiments R26 is methyl.
In some embodiments, R19, R21, R24, and R26 are methyl.
In some embodiments, R21 and R26 are methyl.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R27 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R27 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R27 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R28 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R28 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R28 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R29 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R29 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R29 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R30 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R30 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R30 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R31 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R31 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R31 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R32 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R32 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R32 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R33 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R33 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R33 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R34 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R34 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R34 may be H.
With respect to any relevant formula or structural depiction herein, some non-limiting examples of R35 may include RA, F, Cl, CN, ORA, CF3, NO2, NRARB, CORA, CO2RA, OCORA, NRACORB, CONRARB, etc. In some embodiments, R35 may be H; F; Cl; CF3; OH; NH2; C1-6 alkyl, such as methyl, ethyl, propyl isomers (e.g. n-propyl and isopropyl), cyclopropyl, butyl isomers, cyclobutyl isomers (e.g. cyclobutyl and methylcyclopropyl), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; or C1-6 alkoxy, such as —O-methyl, —O-ethyl, isomers of —O-propyl, —O-cyclopropyl, isomers of —O-butyl, isomers of —O-cyclobutyl, isomers of —O-pentyl, isomers of —O-cyclopentyl, isomers of —O-hexyl, isomers of —O-cyclohexyl, etc. In some embodiments, R35 may be H.
Some embodiments include optionally substituted N,N-diphenyl-4-(5-(6-(1-phenyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)pyrazin-2-yl)aniline. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted 4-methyl-N-(4-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)phenyl)-N-(p-tolyl)aniline. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted N-phenyl-N-(4-(5-(6-(1-phenyl-1H-benzo[d]imidazol-2-yl)pyridin-3-yl)pyrazin-2-yl)phenyl)naphthalen-1-amine. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted N-phenyl-N-(4-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)phenyl)naphthalen-1-amine. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted 2-methyl-N-(4-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)phenyl)-N-(o-tolyl)aniline. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted N-(2,4-dimethylphenyl)-2,4-dimethyl-N-(4-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)phenyl)aniline. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted N,N-diphenyl-4-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)aniline. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted N-(4-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)phenyl)-N-(o-tolyl)naphthalen-1-amine. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted N-phenyl-N-(4-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)phenyl)naphthalen-2-amine. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.
Some embodiments include optionally substituted 9-phenyl-3-(5-(4-(1-phenyl-1H-benzo[d]imidazol-2-yl)phenyl)pyrazin-2-yl)-9H-carbazole. In some embodiments, any substituents may independently be CH3, C2H5, C3H7, F, or CF3. In some embodiments, the compound is unsubstituted.







In some embodiments, a compound of any of the formulae, structures and/or names above (hereinafter referred to as “a subject compound”) may be electroluminescent, or may be fluorescent or phosphorescent. In some embodiments, the compound has fluorescence in the blue or violet visible light range or phosphorescence in the red, orange, yellow, and/or green visible light range. In some embodiments, the compound may have a lowest energy triplet state with an energy over than about 2.5 eV, such as about 2.5 eV to about 4 eV, about 2.5 eV to about 3.5 eV, or about 3 eV to about 3.5 eV.
In some embodiments, a light-emitting device is provided, comprising a compound described above.
In some embodiments, a light emitting device is provided, wherein the compound is an emissive material in an emissive layer.
Some embodiments include a composition comprising a subject compound. A composition comprising a subject compound may further comprise a fluorescent compound or a phosphorescent compound, and may be useful for light emission in devices such as organic light-emitting devices.
In some embodiments, an organic light-emitting device comprises a subject compound. For example, an organic component comprising a subject compound may be disposed between an anode and a cathode. The organic component may further comprise an emissive layer, wherein a subject compound is in the emissive layer. In some embodiments, the device is configured so that electrons can be transferred from the cathode to the organic component and holes can be transferred from the anode to the organic component.
The subject compounds may have high photostability and thermal stability in organic light-emitting devices. The subject compounds may also have well balanced hole and electron injection rates and mobilities. This may provide OLED devices with high efficiencies and/or long lifetimes. The subject compounds may also form amorphous solids, which may make the compounds easy to form into films.
Some embodiments may have a structure represented by FIG. 1. A hole-injection layer 10 is disposed on the anode 5. A hole-transport layer 15 is disposed on the hole-injection layer 15. The emissive layer 20 is disposed on the hole-transport layer 15. An electron-transport layer 30 is disposed on the emissive layer 20, and the cathode 35 is disposed on the electron-transport layer 30.
The anode may be a layer comprising a conventional material such as a metal, mixed metal, alloy, metal oxide or mixed-metal oxide, conductive polymer, and/or an inorganic material such as carbon nanotube (CNT). Examples of suitable metals include the Group 1 metals, the metals in Groups 4, 5, 6, and the Group 8-10 transition metals. If the anode layer is to be light-transmitting, metals in Group 10 and 11, such as Au, Pt, and Ag, or alloys thereof; or mixed-metal oxides of Group 12, 13, and 14 metals, such as indium-tin-oxide (ITO), indium-zinc-oxide (IZO), and the like, may be used. In some embodiments, the anode layer may be an organic material such as polyaniline. The use of polyaniline is described in “Flexible light-emitting diodes made from soluble conducting polymer,” Nature, vol. 357, pp. 477-479 (11 Jun. 1992). In some embodiments, the anode layer can have a thickness in the range of about 1 nm to about 1000 nm.
A cathode may be a layer including a material having a lower work function than the anode layer. Examples of suitable materials for the cathode layer include alkali metals of Group 1, Group 2 metals, Group 12 metals including rare earth elements, lanthanides and actinides, materials such as aluminum, indium, calcium, barium, samarium and magnesium, and combinations thereof. Li-containing organometallic compounds, LiF, and Li2O may also be deposited between the organic layer and the cathode layer to lower the operating voltage. Suitable low work function metals include but are not limited to Al, Ag, Mg, Ca, Cu, Mg/Ag, LiF/Al, CsF, CsF/Al or alloys thereof. In some embodiments, the cathode layer can have a thickness in the range of about 1 nm to about 1000 nm.
In some embodiments, the organic component may comprise at least one light-emitting layer comprising a light-emitting component and a subject compound as a host. The amount of the subject compound in a light-emitting layer may vary. In one embodiment, the amount of a subject compound in a light-emitting layer is in the range of from about 1% to about 99.9% by weight of the light-emitting layer. In another embodiment, the amount of a subject compound in a light-emitting layer is in the range of from about 90% to about 99% by weight of the light-emitting layer. In another embodiment, the amount of a subject compound in a light-emitting layer is about 97% by weight of the light-emitting layer. In some embodiments, the mass of the light-emitting component is about 0.1% to about 10%, about 1% to about 5%, or about 3% of the mass of the light-emitting layer. The light-emitting component may be a fluorescent and/or a phosphorescent compound.
A light-emitting component may comprise an iridium coordination compound such as: bis-{2-[3,5-bis(trifluoromethyl)phenyl]pyridinato-N,C2′}iridium(III)-picolinate; bis(2-[4,6-difluorophenyl]pyridinato-N,C2′)iridium (III) picolinate; bis(2-[4,6-difluorophenyl]pyridinato-N,C2′)iridium(acetylacetonate); Iridium (III) bis(4,6-difluorophenylpyridinato)-3-(trifluoromethyl)-5-(pyridin-2-yl)-1,2,4-triazolate; Iridium (III) bis(4,6-difluorophenylpyridinato)-5-(pyridin-2-yl)-1H-tetrazolate; bis[2-(4,6-difluorophenyl)pyridinato-N,C2′]iridium(III)tetra(1-pyrazolyl)borate; Bis[2-(2′-benzothienyl)-pyridinato-N,C3′]iridium (III)(acetylacetonate); Bis[(2-phenylquinolyl)-N,C2′]iridium (III) (acetylacetonate); Bis[(1-phenylisoquinolinato-N,C2′)]iridium (III) (acetylacetonate); Bis[(dibenzo[f,h]quinoxalino-N,C2′]iridium (III)(acetylacetonate); Tris(2,5-bis-2′-(9′,9′-dihexylfluorene)pyridine)iridium (III); Tris[1-phenylisoquinolinato-N,C2′]iridium (III); Tris-[2-(2′-benzothienyl)-pyridinato-N,C3′]iridium (III); Tris[1-thiophen-2-ylisoquinolinato-N,C3′]iridium (III); Tris[1-(9,9-dimethyl-9H-fluoren-2-yl)isoquinolinato-(N,C3′)iridium (III)); Bis(2-phenylpyridinato-N,C2′)iridium(III)(acetylacetonate) [Ir(ppy)2(acac)]; Bis(2-(4-tolyl)pyridinato-N,C2′)iridium(III)(acetylacetonate) [Ir(mppy)2(acac)]; Bis(2-(4-tert-butyl)pyridinato-N,C2′)iridium (III)(acetylacetonate) [Ir(t-Buppy)2(acac)]; Tris(2-phenylpyridinato-N,C2′)iridium (III) [Ir(ppy)3]; Bis(2-phenyloxazolinato-N,C2′)iridium (III) (acetylacetonate) [Ir(op)2(acac)]; Tris(2-(4-tolyl)pyridinato-N,C2′)iridium(III) [Ir(mppy)3]; Bis[2-phenylbenzothiazolato-N,C2′]iridium (III)(acetylacetonate); Bis[2-(4-tert-butylphenyl)benzothiazolato-N,C2′]iridium(III)(acetylacetonate); Bis[(2-(2′-thienyl)pyridinato-N,C3′)]iridium (III) (acetylacetonate); Tris[2-(9,9-dimethylfluoren-2-yl)pyridinato-(N,C3′)]iridium (III); Tris[2-(9,9-dimethylfluoren-2-yl)pyridinato-(N,C3′)]iridium (III); Bis[5-trifluoromethyl-2-[3-(N-phenylcarbzolyl)pyridinato-N,C2′]iridium(III)(acetylacetonate); (2-PhPyCz)2Ir(III)(acac); etc.






















The thickness of a light-emitting layer may vary. In one embodiment, a light-emitting layer has a thickness in the range of from about 1 nm to about 150 nm or about 200 nm.
In some embodiments, the organic component may further comprise a hole-transport layer disposed between the anode and the light-emitting layer. The hole-transport layer may comprise at least one hole-transport material. Hole-transport materials may include, but are not limited to, an aromatic-substituted amine, a carbazole, a polyvinylcarbazole (PVK), e.g. poly(9-vinylcarbazole); polyfluorene; a polyfluorene copolymer; poly(9,9-di-n-octylfluorene-alt-benzothiadiazole); poly(paraphenylene); poly[2-(5-cyano-5-methylhexyloxy)-1,4-phenylene]; a benzidine; a phenylenediamine; a phthalocyanine metal complex; a polyacetylene; a polythiophene; a triphenylamine; an oxadiazole; copper phthalocyanine; 1,1-Bis(4-bis(4-methylphenyl)aminophenyl)cyclohexane; 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline; 3,5-Bis(4-tert-butyl-phenyl)-4-phenyl[1,2,4]triazole; 3,4,5-Triphenyl-1,2,3-triazole; 4,4′,4′-tris(3-methylphenylphenylamino)triphenylamine (MTDATA); N,N′-bis(3-methylphenyl)N,N′-diphenyl-[1,1′-biphenyl]-4,4′-diamine (TPD); 4,4′-bis[N-(naphthyl)-N-phenyl-amino]biphenyl (α-NPD); 4,4′,4′′-tris(carbazol-9-yl)-triphenylamine (TCTA); 4,4′-bis[N,N′-(3-tolyl)amino]-3,3′-dimethylbiphenyl (HMTPD); 4,4′-N,N′-dicarbazole-biphenyl (CBP); 1,3-N,N-dicarbazole-benzene (mCP); Bis[4-(p,p′-ditolyl-amino)phenyl]diphenylsilane (DTASi); 2,2′-bis(4-carbazolylphenyl)-1,1′-biphenyl (4CzPBP); N,N′N′′-1,3,5-tricarbazoloylbenzene (tCP); N,N′-bis(4-butylphenyl)-N,N′-bis(phenyl)benzidine; or the like.
In some embodiments, the organic component may further comprise an electron-transport layer disposed between the cathode and the light-emitting layer. Examples of electron-transport materials may include, but are not limited to, 2-(4-biphenylyl)-5-(4-tert-butylphenyl)-1,3,4-oxadiazole (PBD); 1,3-bis(N,N-t-butyl-phenyl)-1,3,4-oxadiazole (OXD-7), 1,3-bis[2-(2,2′-bipyridine-6-yl)-1,3,4-oxadiazo-5-yl]benzene; 3-phenyl-4-(1′-naphthyl)-5-phenyl-1,2,4-triazole (TAZ); 2,9-dimethyl-4,7-diphenyl-phenanthroline (bathocuproine or BCP); aluminum tris(8-hydroxyquinolate) (Alq3); and 1,3,5-tris(2-N-phenylbenzimidazolyl)benzene; 1,3-bis[2-(2,2′-bipyridine-6-yl)-1,3,4-oxadiazo-5-yl]benzene (BPY-OXD); 3-phenyl-4-(1′-naphthyl)-5-phenyl-1,2,4-triazole (TAZ), 2,9-dimethyl-4,7-diphenyl-phenanthroline (bathocuproine or BCP); and 1,3,5-tris[2-N-phenylbenzimidazol-z-yl]benzene (TPBI). In one embodiment, the electron transport layer is aluminum quinolate (Alq3), 2-(4-biphenylyl)-5-(4-tert-butylphenyl)-1,3,4-oxadiazole (PBD), phenanthroline, quinoxaline, 1,3,5-tris[N-phenylbenzimidazol-z-yl]benzene (TPBI), or a derivative or a combination thereof.
If desired, additional layers may be included in the light-emitting device. These additional layers may include an electron-injecting layer (EIL), a hole-blocking layer (HBL), an exciton-blocking layer (EBL), and/or a hole-injecting layer (HIL). In addition to separate layers, some of these materials may be combined into a single layer.
In some embodiments, the light-emitting device can include an electron-injecting layer between the cathode layer and the light-emitting layer. Other suitable electron-injecting materials may also be included, and are known to those skilled in the art. Examples of suitable material(s) that can be included in the electron-injecting layer include but are not limited to, an optionally substituted compound selected from the following: aluminum quinolate (Alq3), 2-(4-biphenylyl)-5-(4-tert-butylphenyl)-1,3,4-oxadiazole (PBD), phenanthroline, quinoxaline, 1,3,5-tris[N-phenylbenzimidazol-z-yl]benzene (TPBI) a triazine, a metal chelate of 8-hydroxyquinoline such as tris(8-hydroxyquinoliate)aluminum, and a metal thioxinoid compound such as bis(8-quinolinethiolato) zinc. In one embodiment, the electron-injecting layer is aluminum quinolate (Alq3), 2-(4-biphenylyl)-5-(4-tert-butylphenyl)-1,3,4-oxadiazole (PBD), phenanthroline, quinoxaline, 1,3,5-tris[N-phenylbenzimidazol-z-yl]benzene (TPBI), or a derivative or a combination thereof.
In some embodiments, the device can include a hole-blocking layer, e.g., between the cathode and the light-emitting layer. Various suitable hole-blocking materials that can be included in the hole-blocking layer are known to those skilled in the art. Suitable hole-blocking material(s) include but are not limited to, an optionally substituted compound selected from the following: bathocuproine (BCP), 3,4,5-triphenyl-1,2,4-triazole, 3,5-bis(4-tert-butyl-phenyl)-4-phenyl-[1,2,4]triazole, 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline, and 1,1-bis(4-bis(4-methylphenyl)aminophenyl)-cyclohexane.
In some embodiments, the light-emitting device can include an exciton-blocking layer, e.g., between the light-emitting layer and the anode. In an embodiment, the band gap of the material(s) that comprise exciton-blocking layer is large enough to substantially prevent the diffusion of excitons. A number of suitable exciton-blocking materials that can be included in the exciton-blocking layer are known to those skilled in the art. Examples of material(s) that can compose an exciton-blocking layer include an optionally substituted compound selected from the following: aluminum quinolate (Alq3), 4,4′-bis[N-(naphthyl)-N-phenyl-amino]biphenyl (α-NPD), 4,4′-N,N′-dicarbazole-biphenyl (CBP), and bathocuproine (BCP), and any other material(s) that have a large enough band gap to substantially prevent the diffusion of excitons.
In some embodiments, the light-emitting device can include a hole-injecting layer, e.g., between the light-emitting layer and the anode. A hole-injecting layer may comprise a subject compound as a hole-injecting material. Other examples of suitable hole-injecting material(s) include, but are not limited to, an optionally substituted compound selected from the following: a polythiophene derivative such as poly(3,4-ethylenedioxythiophene (PEDOT)/polystyrene sulphonic acid (PSS), a benzidine derivative such as N,N,N′,N′-tetraphenylbenzidine, poly(N,N′-bis(4-butylphenyl)-N,N′-bis(phenyl)benzidine), a triphenyl amine or phenylenediamine derivative such as N,N′-bis(4-methylphenyl)-N,N′-bis(phenyl)-1,4-phenylenediamine, 4,4′,4′′-tris(N-(naphthylen-2-yl)-N-phenylamino)triphenylamine, an oxadiazole derivative such as 1,3-bis(5-(4-diphenylamino)phenyl-1,3,4-oxadiazol-2-yl)benzene, a polyacetylene derivative such as poly(1,2-bis-benzylthio-acetylene), and a phthalocyanine metal complex derivative such as phthalocyanine copper.
Light-emitting devices comprising a subject compound can be fabricated using techniques known in the art, as informed by the guidance provided herein. For example, a glass substrate can be coated with a high work functioning metal such as ITO which can act as an anode. After patterning the anode layer, a hole-injecting and/or hole-transport layer may be deposited on the anode in that order. A light-emitting layer that includes a light-emitting component, can be deposited on the anode, the hole-transport layer, or the hole-injecting layer. The light-emitting layer may contain a subject compound. An electron-transport layer and/or an electron-injecting layer may deposited in that order on the light-emitting component. The cathode layer, comprising a low work functioning metal (e.g., Mg:Ag), can then be deposited, e.g., by vapor deposition or sputtering. The device may also contain an exciton-blocking layer, an electron blocking layer, a hole blocking layer, a second light-emitting layer, or other layers that can be added to the device using suitable techniques.
In some embodiments, a device comprising the subject compounds can provide a significantly increased device lifetime compared with commercially available compounds. In some embodiments, the devices can provide a T50(h) @ 10000 nit lifetime of at least about 125, 150, 175, 185, and/or 200 hours. In some embodiments, the desired lifetime can be determined by examining the luminescent/emissive decay of the device by measuring the luminescent, e.g., cd/m2, after applying a constant current of a 16 mA to device (corresponding to about 10000 cd/m2) for a device having an active emissive area of about 13.2 mm2.
3. Synthetic Examples
4. Example 1.1
8-1. Example of Synthesis
Synthesis of BE-1







4-(5-bromopyrazin-2-yl)-N,N-diphenylaniline (Compound 1)
A mixture of triphenylamine-4-bronic acid (1.0 g, 3.46 mmol), 2,5-dibromopyrazine (1.81 g, 7.6 mmol), Pd(PPh3)4 (0.2 g, 0.17 mmol) and K2CO3 (1.05 g, 7.6 mmol) in dioxane/water (40 mL/8 mL) was degassed and heated at about 80° C. for about 15 hours. The whole was worked up with ethyl acetate (200 mL), washed with brine. The organic phase was dried over Na2SO4, loaded on silica gel, purified by flash column using the eluents of hexanes to hexanes/dichloromethane (2:1 to 1:1 to 1:2). The desired fraction was collected, and removal of solvent gave a yellow solid (Compound 1) (0.99 g, in 71% yield).




1-Phenyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-1H-benzo[d]imidazole (Compound 2)
A mixture of 2-(5-bromopyridin-2-yl)-1-phenyl-1H-benzo[d]imidazole (1.015 g, 2.9 mmol), bis(pinacolato)diboron (0.76 g, 3 mmol), KOAc (0.49 g, 5 mmol) and Pd(dppf)Cl2 (0.11 g, 0.15 mmol) in dioxane (50 mL) was degassed and heated at about 80° C. for about 15 hours. The whole was worked up with dichloromethane/brine. The organic phase was collected and dried over Na2SO4. After removal of solvent, the resulting brown oil (Compound 2) was used for next step without further purification.




Compound BE-1
A mixture of 4-(5-bromopyrazin-2-yl)-N,N-diphenylaniline (Compound 1) (0.99 g, 2.46 mmol), 1-phenyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-1H-benzo[d]imidazole (Compound 2) (1.15 g, 2.9 mmol), Pd(PPh3)4 (0.22 g, 0.19 mmol) and K2CO3 (1.0 g, 7.2 mmol) in dioxane/water (60 mL/10 mL), was degassed and heated at about 85° C. overnight. Yellow precipitate formed. After filtration, the solid was collected and washed with methanol, then hot dichloromethane (500 mL). A yellow solid (BE-1) was collected, 1.20 g, in 82% yield. Confirmed by LCMS (APCl+): calcd for C40H29N6 (M+H): 593; found 593.
Synthesis of BE-2







4-Bromo-N-(2-(phenylamino)phenyl)benzamide (Compound 3)
To a solution of 4-bromo-benzoyl chloride (11 g, 50 mmol) in anhydrous dichloromethane (DCM) (100 ml), was added N-phenylbenzene-1,2-diamine (10.2 g, 55 mmol), then triethylamine (TEA) (17 ml, 122 mmol) slowly. The whole was stirred at room temperature (RT) overnight. Filtration gave a white solid 3 (6.5 g). The filtrate was worked up with water (300 ml), then extracted with DCM (300 mL) three times. The organic phase was collected and dried over MgSO4, concentrated and recrystallized in DCM/hexanes to give another portion of white solid 3 (10.6 g). Total amount of product 3 is 17.1 g, in 93% yield.




2-(4-bromophenyl)-1-phenyl-1H-benzo[d]imidazole (4)
To a suspension of amide 3 (9.6 g, 26 mmol) in anhydrous 1,4-dioxane (100 mL) was added phosphorus oxychloride (POCl3) (9.2 mL, 100 mmol) slowly. The whole was then heated at 100° C. overnight. After cooling to RT, the mixture was poured into ice (200 g) with stirring. Filtration, followed by recrystallization in DCM/hexanes gave a pale grey solid 4 (8.2 g, in 90% yield).




1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole (5)
A mixture of Compound 4 (0.70 g, 2 mmol), bis(pinacolate)diborane (0.533 g, 2.1 mmol), bis(diphenylphosphino)ferrocene]dichloropalladium (Pd(dppf)Cl2) (0.060 g, 0.08 mmol) and anhydrous potassium acetate (KOAc) (0.393 g, 4 mmol) in 1,4-dioxane (20 ml) was heated at about 80° C. under argon overnight. After cooling to RT, the whole was diluted with ethyl acetate (80 ml) then filtered. The solution was absorbed on silica gel, then purified by column chromatography (hexanes/ethyl acetate 5:1 to 3:1) to give a white solid 5 (0.64 g, in 81% yield).




4-(5-bromopyrazin-2-yl)-N,N-di-p-tolylaniline (Compound 6)
A mixture of (4-(di-p-tolylamino)phenyl)boronic acid (0.74 g, 2.33 mmol), 2,5-dibromopyrazine (1.19 g, 5 mmol), Pd(PPh3)4 (0.14 g, 0.12 mmol) and K2CO3 (0.69 g, 5 mmol) in dioxane/water (80 mL/10 mL) was degassed and heated at about 80° C. overnight. The whole was diluted with ethyl acetate (250 mL), washed with brine, dried over Na2SO4, loaded on silica gel column and purified by flash column using eluents of hexanes to hexanes/dichloromethane (3:1). The desired fraction was collected, and a yellow solid (6) was obtained after removal of solvents, 0.63 g, in 63% yield.




Compound BE-2
A mixture of 4-(5-bromopyrazin-2-yl)-N,N-di-p-tolylaniline (Compound 6) (0.63 g, 1.46 mmol), 1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole (0.58 g, 1.46 mmol) (Compound 5), Pd(PPh3)4 (0.115 g, 0.1 mmol) and K2CO3 (0.414 g, 3 mmol) in dioxane/water (50 mL/10 mL) was degassed and heated at about 90° C. overnight. The resulting solution was diluted with ethyl acetate (250 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to dichloromethane to dichloromethane/ethyl acetate 4:1. The desired yellow fraction was collected, concentrated, recrystallized in dichloromethane/hexanes to give a yellow crystalline solid (Compound 6) (0.74 g, in 82% yield). Confirmed by LCMS (APCl+): calcd for C43H34N5 (M+H): 620; found: 620.
Synthesis of BE-3










N-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)naphthalen-1-amine (Compound 7)
A mixture of N-(4-bromophenyl)-N-phenylnaphthalen-1-amine (7.14 g, 19.1 mmol), bis(pinacolato)diboron (5.08 g, 20 mmol), Pd(dppf)Cl2 (0.73 g, 1.0 mmol) and KOAc (4.9 mmol, 50 mmol) in dioxane (100 mL) was degassed and heated at about 85° C. for 15 hours. The resulting mixture was poured into ethyl acetate (250 mL), filtered off precipitate, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane (8:1 to 6:1 to 2:1). The desired fraction was collected, and after removal of solvent to give a white solid (Compound 7) (6.0 g, in 75% yield).




N-(4-(5-bromopyrazin-2-yl)phenyl)-N-phenylnaphthalen-1-amine (Compound 8)
A mixture of N-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)naphthalen-1-amine (Compound 7) (2.91 g, 6.91 mmol), 2,5-dibromopyrazine (3.56 g, 13.8 mmol), Pd(PPh3)4 (0.346 g, 0.3 mmol), K2CO3 (1.93 g, 14 mmol) in dioxane/water (80 mL/15 mL), was degassed and heated at about 85° C. overnight. The resulting mixture was diluted with ethyl acetate (250 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 4:1 to 2:1 to 3:2). The desired fraction was collected, after removal of solvent to give a yellow solid (Compound 8) (2.2 g, in 70.4% yield).




Compound BE-3
a mixture of N-(4-(5-bromopyrazin-2-yl)phenyl)-N-phenylnaphthalen-1-amine (Compound 8) (1.17 g, 2.6 mmol), 1-phenyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-1H-benzo[d]imidazole (Compound 2) (2.9 mmol), Pd(PPh3)4 (0.138 g, 0.12 mmol) and K2CO3 (0.69 g, 5 mmol) in dioxane/water (70 mL/16 mL) was degassed and heated at about 90° C. overnight. The resulting mixture was diluted with ethyl acetate (200 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes/dichloromethane 1:1 to 1:2 to dichloromethane to dichloromethane/ethyl acetate 10:1 to 4:1. The desired fraction was collected and concentrated to give a yellow solid (1.39 g, in 83% yield). Confirmed by LCMS (APCl+): calcd for C44H31N6 (M+H): 643; found: 643.




Compound BE-4
A mixture of N-(4-(5-bromopyrazin-2-yl)phenyl)-N-phenylnaphthalen-1-amine (Compound 8)(1.11 g, 2.46 mmol), 1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole (Compound 5) (0.95 g, 2.4 mmol), Pd(PPh3)4 (0.14 g, 0.12 mmol) and K2CO3 (0.69 g, 5 mmol) in dioxane/water (70 mL/15 mL) was degassed and heated at 85° C. overnight. The mixture was diluted with ethyl acetate (200 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes/dichloromethane 1:1 to dichloromethane to dichloromethane/ethyl acetate 9:1. The desired fraction was collected, concentrated and recrystallized in dichloromethane/hexanes to give yellow solid (BE-4) (1.50 g, in 98% yield). Confirmed by LCMS (APCl+): calcd for C45H32N5 (M+H): 642; Found: 642.







di-o-tolylamine (Compound 9)
A mixture of o-toluidine (6.05 g, 56.5 mmol), 1-bromo-2-methylbenzene (8.5 g, 50 mmol), Pd(dppf)Cl2 and sodium tert-butoxide (9.6 g, 0.1 mmol) in toluene (120 mL) was degassed and heated at about 100° C. overnight. The mixture was purified by flash column using eluents of hexanes/dichloromethane 2:1 to give a white solid (Compound 9) (8.84 g, in 89.7% yield).




2-methyl-N-phenyl-N-(o-tolyl)aniline (Compound 10)
A mixture of di-o-tolylamine (Compound 9) (6.00 g, 30.4 mmol), iodobenzene (12.2 g, 60 mmol), Pd(OAc)2 (0.34 g, 1.5 mmol), P(t-Bu)3 (0.6 g, 3 mmol), sodium tert-butoxide (5.76 g, 60 mmol) in toluene (120 mL) was degassed and heated at about 120° C. for 40 hours. The resulting mixture was diluted with ethyl acetate (200 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to give a white solid (Compound 10) (8.2 g, in 98% yield).




N-(4-bromophenyl)-2-methyl-N-(o-tolyl)aniline (Compound 11)
To a solution of 2-methyl-N-phenyl-N-(o-tolyl)aniline (Compound 10) (8.2 g, 30 mmol) in dichloromethane (DCM) (100 mL), was added n-bromosuccinimide (NBS) (5.34 g, 30 mmol) at about 0° C. and stirred for about 4 hours. The resulting mixture was worked up with dichloromethane/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 9:1. The desired fraction was collected, and removal of solvent gave a white solid (Compound 11) (10.7 g, in 100% yield).




2-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(o-tolyl)aniline (Compound 12)
A mixture of N-(4-bromophenyl)-2-methyl-N-(o-tolyl)aniline (Compound 11) (10.7 g, 30.4 mmol), bis(pinacolato)diboron (10.16 g, 40 mmol), KOAc (6.0 g, 0.1 mol), Pd(OAc)2 (0.336 g, 1.5 mmol), Bis(2-diphenylphosphinophenyl)ether (1.614 g, 3 mmol) in dioxane (100 mL) was degassed and heated at about 100° C. overnight. The resulting mixture was worked up with ethyl acetate/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 4:1. The desired fraction was collected and the solvent was removed to give a colorless oil (Compound 12) (3.3 g, in 27% yield).




N-(4-(5-bromopyrazin-2-yl)phenyl)-2-methyl-N-(o-tolyl)aniline (Compound 13)
2-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(o-tolyl)aniline (Compound 12) (3.3 g, 8.3 mmol), 2,5-dibromopyrazine (4.27 g, 16 mmol), Pd(PPh3)4 (0.46 g, 0.4 mmol), K2CO3 (2.21 g, 16 mmol) in dioxane/water (100 mL/16 mL), was degassed and heated at about 80° C. overnight. The resulting mixture was worked up with ethyl acetate/brine, dried over Na2SO4, loaded on silica gel, purified by flash column using eluents of hexanes to hexanes/dichloromethane 9:1 to 6:1 to 4:1). The desired fraction was collected, and a yellow solid (Compound 13) was obtained after removal of solvents (1.9 g, in 53% yield).




Compound BE-5
a mixture of N-(4-(5-bromopyrazin-2-yl)phenyl)-2-methyl-N-(o-tolyl)aniline (Compound 13) (1.9 g, 4.4 mmol), 1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole (Compound 5) (1.75 g, 4.4 mmol), Pd(PPh3)4 (0.25 g, 0.22 mmol), K2CO3 (1.38 g, 10 mmol) in dioxane/water (100 mL/16 mL), was degassed and heated at about 90° C. overnight. The resulting mixture was worked up with ethyl acetate/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 8:1 to 4:1 to dichloromethane/ethyl acetate 9:1. The desired fraction was collected, and after removal of solvent and recrystallization, gave a yellow solid (Compound BE-5) (2.2 g, in 80.6% yield). Confirmed by LCMS (APCl+): calcd for C43H34N5 (M+H): 620; found: 620.
Synthesis of BE-6







Bis(2,4-dimethylphenyl)amine (Compound 14)
A mixture of 2,4-dimethylaniline (6.05 g, 50 mmol), 2,4-dimethylbromobenzene (9.25 g, 50 mmol), Pd(dppf)Cl2 (0.88 g, 1.2 mmol), sodium tert-butoxide (KOBut) (9.6 g, 0.1 mmol) in toluene (120 mL) was degassed and heated at 100° C. overnight. The resulting mixture was worked up with dichloromethane/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 9:1. After removal of solvent, a liquid was obtained (9.45 g, in 84% yield).




N-(2,4-dimethylphenyl)-2,4-dimethyl-N-phenylaniline (Compound 15)
A mixture of bis(2,4-dimethylphenyl)amine (Compound 14) (9.4 g, 41.8 mmol), iodobenzene (17.14 g, 84 mmol), Pd(OAc)2 (0.47 g, 2.1 mmol), P(t-Bu)3 (0.848 g, 4.2 mmol), sodium tert-butoxide (7.68 g, 80 mmol) in toluene (120 mL) was degassed and heated at 120° C. for 16 hours. The resulting mixture was poured into ethyl acetate (250 mL), washed with brine, dried over Na2SO4, loaded on silicagel and purified by flash column using eluent of hexanes. After removal of solvent, an oil (Compound 15) was obtained (12.4 g, in 98.6% yield).




N-(4-bromophenyl)-N-(2,4-dimethylphenyl)-2,4-dimethylaniline (Compound 16)
To a solution of N-(2,4-dimethylphenyl)-2,4-dimethyl-N-phenylaniline (Compound 15) (12.4 g, 41 mmol) in dichloromethane (200 mL), was added NBS (8.01 g, 45 mmol) at 0° C. The whole was stirred for about 3 hours and worked up with brine. The organic phase was dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes. After removal of solvents, a colorless oil (Compound 16) was obtained (15 g, in 96% yield).




N-(2,4-dimethylphenyl)-2,4-dimethyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)aniline (Compound 17)
A mixture of N-(4-bromophenyl)-N-(2,4-dimethylphenyl)-2,4-dimethylaniline (Compound 16) (15 g, 39.5 mmol), bis(pinacolato)diboron (10.41 g, 41 mmol), KOAc (7.84 g, 80 mmol), Bis(2-diphenylphosphinophenyl)ether (3.23 g, 6 mmol) and Pd(OAc)2 (0.44 g, 2 mmol) in dioxane (100 mL) was degassed and heated at about 100° C. overnight. The resulting mixture was poured into ethyl acetate (200 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/ethyl acetate 18:1. After removal of solvents, a white solid (Compound 17) was obtained (14 g, in 83% yield).




N-(4-(5-bromopyrazin-2-yl)phenyl)-N-(2,4-dimethylphenyl)-2,4-dimethylaniline (Compound 18)
A mixture of N-(2,4-dimethylphenyl)-2,4-dimethyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)aniline (Compound 17) (6.0 g, 14 mmol), 2,5-dibromopyrazine (7.74 g, 30 mmol), Pd(PPh3)4 (0.5 g, 0.43 mmol), K2CO3 (4.14 g, 30 mmol) in dioxane/water (80 mL/17 mL) was degassed and heated at about 80° C. overnight. The resulting mixture was poured into ethyl acetate (200 mL), washed with brine, dried over Na2SO4, then loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 9:1 to 6:1 to 7:3. The desired yellow fraction was collected, and a yellow solid (Compound 18) was obtained after removal of solvents (3.83 g, 60% yield).




Compound BE-6
A mixture of N-(4-(5-bromopyrazin-2-yl)phenyl)-N-(2,4-dimethylphenyl)-2,4-dimethylaniline (Compound 18) (1.67 g, 3.65 mmol), 1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole (Compound 5) (1.445 g, 3.65 mmol), Pd(PPh3)4 (0.21 g, 0.18 mmol), K2CO3 (0.966 g, 7 mmol) in dioxane/water (50 mL/10 mL) was degassed and heated at about 100° C. overnight. The resulting mixture was poured into ethyl acetate (200 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 1:1 to dichloromethane to dichloromethane/ethyl acetate 90:5. The desired yellow fraction was collected. After removal of solvent, a yellow solid (BE-6) was obtained (2.2 g, in 93% yield). Confirmed by LCMS (APCl+): calcd for C45H38N5 (M+H): 648; Found: 648.







4-(5-bromopyrazin-2-yl)-N,N-diphenylaniline (Compound 19)
A mixture of (4-(diphenylamino)phenyl)boronic acid (3.26 g, 11.3 mmol), 2,5-dibromopyrazine (5.82 g, 22.6 mmol), Pd(PPh3)4 (0.635 g, 0.55 mmol), K2CO3 (3.45 g, 25 mmol) in dioxane/water (100 mL/16 mL) was degassed and heated at about 85° C. for about 20 hours. The resulting mixture was poured into ethyl acetate (250 mL), washed with brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 4:1. After removal of solvent, a yellow solid (Compound 19) was obtained (3.1 g, in 68.2% yield).




Compound BE-7
A mixture of 4-(5-bromopyrazin-2-yl)-N,N-diphenylaniline (Compound 19) (1.54 g, 3.83 mmol), 1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole (Compound 5) (1.52 g, 3.83 mmol), Pd(PPh3)4 (0.22 g, 0.19 mmol), K2CO3 (1.104 g, 8 mmol) in dioxane/water (100 mL/15 mL) was degassed and heated at about 90° C. for about 16 hours. The resulting mixture was poured into ethyl acetate (250 mL), washed with brine, concentrated and yellow precipitate formed. Filtration and washing with ethyl acetate gave a solid and filtrate. The filtrate was loaded n silica gel was loaded on silica gel and purified by flash column using eluents of hexanes to dichloromethane to dichloromethane/ethyl acetate (9:1 to 4:1). The desired fraction was collected. The solid from the filtration was dissolved in dichloromethane, purified by flash column using eluents of hexanes to dichloromethane to dichloromethane/ethyl acetate 9:1. The desired fraction was collected. Both desired fractions from the chromatography were combined, after removal of solvent, the solid was recrystallized in dichloromethane/ethyl acetate to give a yellow solid (BE-7), 1.94 g in 85.6% yield. Confirmed by LCMS (APCl+): calcd for C41H30N5 (M+H): 592; found: 592.
Synthesis of BE-8







N-(o-tolyl)naphthalen-1-amine (Compound 20)
A mixture of 1-aminonaphthalene (7.15 g, 50 mmol), 1-bromo-2-methylbenzene (8.5 g, 50 mmol), Pd(dppf)Cl2 (1.0 g, 1.36 mmol), sodium tert-butoxide (9.6 g, 0.1 mol) in toluene (120 mL) was degassed and heated at about 100° C. overnight. The resulting mixture was worked up with ethyl acetate/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 9:1. After removal of solvents, an oil (Compound 20) was obtained, 10.2 g in 91.5% yield.




N-(4-bromophenyl)-N-(o-tolyl)naphthalen-1-amine (Compound 21)
A mixture of N-(o-tolyl)naphthalen-1-amine (Compound 20) (2.0 g, 8.6 mmol), 1-bromo-4-iodobenzene (8.67 g, 30 mmol), Pd(dppf)Cl2 (0.365 g, 0.5 mmol), potassium tert-butoxide (1.96 g, 20 mmol) in toluene was degassed and heated at 110° C. overnight. The resulting mixture was worked up with ethyl acetae/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 9:1. After removal of solvents, a yellow solid (Compound 21) was obtained, 0.45 g in 13.5% yield.




N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(o-tolyl)naphthalen-1-amine (Compound 22)
A mixture of N-(4-bromophenyl)-N-(o-tolyl)naphthalen-1-amine (Compound 21) (0.87 g, 2.24 mmol), bis(pinacolato)diboran (0.635 g, 2.5 mmol), Pd(dppf)Cl2 (81.8 mg, 0.11 mmol), KOAc (0.49 g, 5 mmol) in dioxane (50 mL) was degassed and heated at 80° C. overnight. The resulting mixture was worked up with ethyl acetate/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/ethyl acetate 18:1. After removal of solvents, a yellow solid (Compound 22) was obtained, 0.55 g in 56% yield.




N-(4-(5-bromopyrazin-2-yl)phenyl)-N-(o-tolyl)naphthalen-1-amine (Compound 23)
A mixture of N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(o-tolyl)naphthalen-1-amine (Compound 22) (0.55 g, 1.26 mmol), 2,5-dibromopyrazine (0.77 g, 3.0 mmol), Pd(PPh3)4 (0.1 g, 0.09 mmol), K2CO3 (0.414 g, 3 mmol) in dioxane/water (40 mL/8 mL) was degassed and heated at 80° C. overnight. The resulting mixture was worked up with ethyl acetate/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes/dichloromethane 9:1 to 3:2. After removal of solvents, a yellow solid (Compound 23) was obtained, 0.44 g in 75% yield.




Compound BE-8
A mixture of N-(4-(5-bromopyrazin-2-yl)phenyl)-N-(o-tolyl)naphthalen-1-amine (Compound 23) (0.44 g, 0.94 mmol), 1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole (Compound 5) (0.374 g, 0.94 mmol), Pd(PPh3)4 (0.058 g, 0.05 mmol), K2CO3 (0.276 g, 2 mmol) in dioxane/water (40 mL/8 mL) was degassed and heated at about 90° C. for 5 hours. The resulting mixture was worked up with ethyl acetate/brine, dried over Na2SO4, loaded on silica gel and purified by flash column using eluents of hexanes to hexanes/dichloromethane 4:1 to 1:1 to dichloromethane/ethyl acetate 10:1. The desired fraction was collected, after removal of solvents, the solid was recrystallized in dichloromethane/hexanes to give a yellow solid (BE-8), 0.18 g in 29% yield. Confirmed by LCMS (APCl+): calcd for C46H34N5 (M+H): 656; Found: 656.
Example of OLED Device Configuration and Performance
Example 2
ITO coated glass substrates will be cleaned by ultrasound in water, acetone, and consecutively in 2-propanol, baked at 110° C. for 3 hours, followed by treatment with oxygen plasma for 5 min. A layer of PEDOT: PSS (Baytron P purchased from H.C. Starck) will be spin-coated at 3000 rpm onto the pre-cleaned and O2-plasma treated (ITO)-substrate and annealed at about 180° C. for 30 min, to yield a thickness of around 55 nm. In a glove-box hosted vacuum deposition system at a pressure of 10−7 torr (1 torr=133.322 Pa), DTASi will be first deposited on top of PEDOT/PSS layer at deposition rate of 0.06 nm/s, yielding a 30 nm thick film. Then the BE-2 will be heated and deposited on top of DTASi, yielding about a 5 nm thick film, followed by co-deposition of BE-2 and Ir(PIQ)2(acac) at depositions rates of about 0.06 nm/s to form a 5 nm thick layer, and deposition of another BE-2 layer having a thickness of about 5 nm. Then 1,3,5-tris(N-phenylbenzimidizol-2-yl)benzene (TPBI) at deposition rate around 0.06 nm/s will be deposited on the BE-2 layer to form a 40 nm thick film. LiF (1.0 nm) and Al (100 nm) will be then deposited successively at deposition rates of 0.005 and 0.2 nm/s, respectively. Each individual device will have areas of 0.14 cm2.
Example 3
All spectra will be measured with an Ocean Optics HR 4000 spectrometer and I-V-L characteristics were taken with a Keithley 2400 SourceMeter and Newport 2832-C power meter and 818 UV detector. All device operation will be performed inside a nitrogen-filled glove-box. An example of a configuration of the device (Device-A) is shown in FIG. 4.
It is anticipated that upon determining the luminescent efficiency and power efficiency as a function of luminance of Device-A, a plot of the electroluminescence spectrum of Device-A, and the CRI of Device A, BE-2 will be suitable as a host material in hybrid OLED devices.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of any claim. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
Groupings of alternative elements or embodiments disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, the claims include all modifications and equivalents of the subject matter recited in the claims as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is contemplated unless otherwise indicated herein or otherwise clearly contradicted by context.
In closing, it is to be understood that the embodiments disclosed herein are illustrative of the principles of the claims. Other modifications that may be employed are within the scope of the claims. Thus, by way of example, but not of limitation, alternative embodiments may be utilized in accordance with the teachings herein. Accordingly, the claims are not limited to embodiments precisely as shown and described.

## Claims

1. A compound represented by a formula:


HT-[Ph1]r-Py-Het-ET

wherein HT is optionally substituted diphenylamine or optionally substituted phenyl(naphthyl)amine,
each Ph1 is independently optionally substituted p-phenylene, wherein the p-phenylene directly bonded to HT may optionally form a bond to a phenyl of HT to form a three ring system;
Py is optionally substituted pyrazin-2,5-ylene;
Het is optionally substituted p-phenylene or optionally substituted pyridin-2,5-ylene;
ET is optionally substituted benzimidazol-2-yl, optionally substituted benzoxazol-2-yl, or optionally substituted benzothiazol-2-yl; and
r is 1, 2, 3.

2. The compound of claim 1, further represented by a formula:


HT-Ph1a-Ph1b-Ph1c-Py-Het-ET

wherein Ph1a is optionally substituted p-phenylene, or HT-Ph1a is 9-phenylcarbazol-3-yl; and Ph1b and Ph1c are independently a bond.

3. The compound of claim 1, wherein r is 1.

4. The compound of claim 1, wherein ET is optionally substituted 1-phenyl-1H-benzo[d]imidazol-2-yl.

5. The compound of claim 1, wherein HT is

6. The compound of claim 1, wherein ET is

7. The compound of claim 1, wherein the compound is:

8. The compound of claim 1, wherein the compound is electroluminescent.

9. The compound of claim 8, wherein the compound has a lowest energy triplet having an energy of about 2.5 eV to about 4 eV.

10. A light emitting layer comprising the compound of claim 1.

11. A light emitting device, comprising:
an anode layer comprising a high work function metal;
a cathode layer comprising a low work function metal; and
a light emitting layer comprising a compound of claim 1.

12. The compound of claim 1, wherein Het is optionally substituted p-phenylene.

13. The compound of claim 1, wherein Het is optionally substituted pyridin-2,5-ylene.

14. The compound of claim 1, wherein r is 2.

15. The compound of claim 1, wherein r is 3.